Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081911 | 0.85 | EP300 (0.38) | EP300 | |
| SCHEMBL18081720 | 0.83 | LRRK2 (0.32) | — | |
| SCHEMBL16631399 | 0.80 | NOTUM (0.49) | DDB1CRBNMAOA | |
| SCHEMBL16631688 | 0.77 | — | — | |
| SCHEMBL19663162 | 0.76 | DHFR (0.33) | — | |
| SCHEMBL18081748 | 0.73 | EP300 (0.40) | EP300 | |
| SCHEMBL16631614 | 0.73 | LMNA (0.50) | — | |
| SCHEMBL16257876 | 0.73 | TBK1 (0.32) | — | |
| SCHEMBL18080382 | 0.72 | — | — | |
| SCHEMBL16631717 | 0.72 | DDB1 (0.38) | DDB1CRBNMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | DDB1 620/4885CRBN 2319/4885MAOA 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.